News
RMD
229.92
+0.25%
0.58
With EPS Growth And More, ResMed (NYSE:RMD) Makes An Interesting Case
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Simply Wall St. · 3d ago
Insider Sell: Resmed
Insider Sell: Resmed
MT Newswires · 4d ago
Looking Into ResMed's Return On Capital Employed
Benzinga · 11/01 16:35
Research Alert: CFRA Maintains Sell Opinion On Shares Of Resmed Inc.
Research Alert: CFRA Maintains Sell Opinion On Shares Of Resmed Inc.
MT Newswires · 10/31 18:17
ResMed shares fall 6% despite reporting FQ1 2023 revenue growth
Seekingalpha · 10/28 19:10
RBC Capital Maintains Sector Perform on ResMed, Raises Price Target to $254
Benzinga · 10/28 14:47
Is ResMed Inc.'s (NYSE:RMD) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Most readers would already be aware that ResMed's (NYSE:RMD) stock increased significantly by 9.4% over the past month...
Simply Wall St. · 10/28 14:15
Where ResMed Stands With Analysts
Benzinga · 10/28 13:05
--RBC Lifts Price Target on ResMed to $254 From $252, Maintains Sector Perform Rating
--RBC Lifts Price Target on ResMed to $254 From $252, Maintains Sector Perform Rating
MT Newswires · 10/28 08:57
Keybanc Maintains Overweight on ResMed, Raises Price Target to $280
Benzinga · 10/28 08:43
--KeyBanc Adjusts ResMed's Price Target to $280 From $276, Keeps Overweight Rating
--KeyBanc Adjusts ResMed's Price Target to $280 From $276, Keeps Overweight Rating
MT Newswires · 10/28 08:25
BRIEF-Resmed Announces Results For Q1 Of Fiscal Year 2023
Reuters · 10/27 21:19
ResMed declares $0.44 dividend
Seekingalpha · 10/27 21:03
ResMed Q1 EPS $1.51 Misses $1.52 Estimate, Sales $950.29M Beat $941.17M Estimate
Benzinga · 10/27 20:42
ResMed Non-GAAP EPS of $1.51 misses by $0.09, revenue of $950.3M beats by $4.39M
Seekingalpha · 10/27 20:17
More
Webull provides a variety of real-time RMD stock news. You can receive the latest news about Resmed through multiple platforms. This information may help you make smarter investment decisions.
About RMD
ResMed Inc. is a holding company. The Company, through its subsidiaries, is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep-disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. It also offers software solutions for a variety of out-of-hospital care providers. The Company has two segments: Sleep and Respiratory Care and the Software-as-a-Service. Sleep apnea includes obstructive sleep apnea and other respiratory disorders that occur during sleep. Its cloud-based digital health applications, along with its devices, are designed to provide connected care to improve patient outcomes. The Company's portfolio of products includes ventilation devices, diagnostic products, mask systems, headgear and other accessories, dental devices and cloud-based software informatics solutions.